New Study Validates Payer/Physician Use of AI to Cut Wasteful Spending on High-Cost, Low-Value Cancer Drugs
The Research Consortium announced the release of a new study today that challenges common misconceptions about combination cancer therapies, their cost, and their value. It provides payers, physicians and patients with insight as to how they can avoid wasteful spending on high-cost, low-clinical-value cancer drugs.
The concurrent (on- and off-label) use of multiple FDA-approved drugs to treat advanced cancer is now common-place; however, there are 4.5+ million possible 1-, 2- and 3-drug combinations of the ~300 available cancer drugs. As a result….Read More